Skip to main content

Table 1 Incidence and duration of paralytic relapses in EAE mice after cell treatment

From: Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis

Treatment group Incidence of relapsea, b Relapse rate (%) Duration of relapsec
Median Mean ± SD CI (95 %)
Control (PBS) 31 (44) 70.5 20.0 17.0 ± 9.6 13.6–20.4
MICCop 5 (30) 16.7 4.0 6.6 ± 5,0 2.2–11.0
MIC 4 (7) 57.1 6.5 9.50 ± 8.4 1.3–17.7
SPCCop 8 (15) 53.3 13.5 14.5 ± 6,6 9.9–19.1
UVC-SPCCop 15 (15) 100 24.0 19.6 ± 7.7 15.7–23.5
  1. Treatment groups were compared using Fisher’s exact test (incidence of relapse) and One-tail Mann–Whitney U test (duration of relapse): * p < 0.05, ** p < 0.01, *** p < 0.001
  2. CI confidence interval; EAE experimental autoimmune encephalomyelitis; MIC mitomycin C-induced cells; MIC Cop Copaxone®-loaded mitomycin C-induced cells; PBS phosphate-buffered saline; SD standard deviation; SPC Cop Copaxone®-loaded splenocytes; UVC-SPC Cop Copaxone®-loaded ultraviolett C-irradiated splenocytes
  3. aIncidence of relapse: number of mice with relapse (total number of animals) in treatment group
  4. b Incidence of relapse MICCop vs. control, *** p < 0.0001; MIC vs. control, p = 0.66; SPCCop vs. control, * p = 0.026; UVC-SPCCop vs. control, * p = 0.034; MICCop vs. MIC,* p = 0.045; MICCop vs. SPCCop, *** p < 0.0001; MICCop vs. UVC-SPCCop, * p = 0.016; MIC vs. SPCCop, p = 1.00; MIC vs. UVC-SPCCop, * p = 0.022; SPCCop vs. UVC-SPCCop, ** p = 0.006
  5. c Duration of relapse MICCop vs. control, * p = 0.017; MIC vs. control, p = 0.063; SPCCop vs. control, p = 0.266; UVC-SPCCop vs. control, p = 0.755; MICCop vs. MIC, p = 0.476; MICCop vs. SPCCop, * p = 0.024; MICCop vs. UVC-SPCCop, ** p = 0.005; MIC vs. SPCCop, p = 0.107; MIC vs. UVC-SPCCop, * p = 0.026; UVC-SPCCop vs. SPCCop, p = 0.945
\